(RTTNews) – Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analogue. In the trial, adults with type 2 diabetes randomised to once-weekly insulin icodec achieved similar blood sugar control and a similar safety profile compared with adults with type 2 diabetes randomised to once-daily insulin glargine U100.
The 26-week, randomised, double-blind, double-dummy, treat-to-target phase 2 clinical trial involved 247 insulin-naïve adults with type 2 diabetes inadequately controlled with metformin with or without a DPP-4i.
The primary endpoint showed that the change from baseline to week 26 in blood sugar control (HbA1c) was similar in participants receiving once-weekly insulin icodec compared to once-daily insulin glargine U100.
The company expects to initiate the phase 3 clinical development programme for once-weekly insulin icodec later in 2020.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.